Vyome Holdings, Inc. (HIND)
| Market Cap | 19.02M |
| Revenue (ttm) | 344,591 |
| Net Income (ttm) | -9.34M |
| Shares Out | 5.64M |
| EPS (ttm) | -13.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,892 |
| Open | 3.360 |
| Previous Close | 3.360 |
| Day's Range | 3.300 - 3.430 |
| 52-Week Range | 1.750 - 16.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 15.00 (+345.1%) |
| Earnings Date | Apr 29, 2026 |
About HIND
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts. [Read more]
Financial Performance
In 2024, Vyome Holdings's revenue was $256,944, a decrease of -38.23% compared to the previous year's $415,940. Losses were -$1.45 million, 81.0% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for HIND stock is "Strong Buy" and the 12-month stock price target is $15.0.
News
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare co...
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In ...
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.
Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
“From 2019 to 2025, the biomarker landscape has seen a surge in strategic collaborations, licensing, and acquisitions, driven by the growing demand for precision medicine, companion diagnostics, and t...
Vyome Holdings Announces Results of Annual Shareholder Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Annual meeting of Vyome Holdings Inc.
Vyome Holdings Acquires MIT AI Spinout Oculo Health
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo,...
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the...
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technolog...
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase...
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an ...
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced its Board of Directors has agreed to conduct a ...
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets wit...
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with l...
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large marke...
Vyome Announces New Board of Directors with Deep MIT and AI Ties
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potentia...
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced ...
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Port...